PET-CT upstaging of unilateral operable breast cancer and its correlation with molecular subtypes

Abstract

Context: Prognosis and survival rates for breast cancer vary greatly depending on the cancer stage of the patient. Instead of a step-by-step approach using multiple investigations, we can get all the information about the metastatic load of the disease in PET-CT imaging by one single investigation. There is also a correlation between prognosis, FDG uptake, and molecular subtype of breast cancer (Luminal A, Luminal B, Human epidermal growth factor receptor 2 (HER2) positive and Triple-negative). Pre-treatment baseline PET-CT scan was done in 156 unilateral early and operable breast cancer patients from November 2017 to April 2019 in our prospective observational study.

Aims:

• To evaluate the utility of PET-CT in staging and upstaging of early and operable breast cancer by detection of unsuspected lymph nodes and distant organ metastases.

• To determine the prognostic association between SUVmax of the primary breast lesion in the upstaged cases and the molecular subtypes.

Results:

• Thus, PET-CT can serve as one-stop imaging in unilateral operable early breast cancer patients for upstaging and prognostication based on the correlation of SUVmax with molecular subtypes of breast lesions in patients who will surely benefit from whole-body imaging.

• Out of 156 patients, approximately 27 patients were upstaged after pre-treatment PET CT.

• Six patients were upstaged to stage IIIC and 21 patients were upstaged to IV.

• Regional nodes like internal mammary and supraclavicular nodes were detected in 7 patients and 5 patients, respectively, out of 156 patients.

• Non-regional distant nodes and organ metastases were detected in 11 and 18 patients out of 156 patients.

• Most common molecular subtype detected in the upstaged cases in our study was Luminal A (13 patients) followed by Triple negative (6), Luminal B (3) and HER2-neu-positive subtypes (1).

Conclusions:

• FDG PET-CT is a substantial modality to provide information on regional, non regional lymph nodes and distant metastases in early operable breast cancer.

• It helps in evaluating the whole body metastatic burden in a single sitting, therefore, reducing the need for multiple investigations.

• SUVmax association of the index lesion with molecular subtype in the FDG PET scanning can serve as a prognostication factor in operable early breast cancer patients.

Keywords

Breast cancer - metastases - molecular subtypes - operable - PET-CT

Publikationsverlauf

Eingereicht: 08. Februar 2020

Angenommen: 21. Juni 2020

Artikel online veröffentlicht:
19. Juli 2021

• References

• 1 Tewari A, Sundaram SP, Subramanyam P. Role of preoperative 18-FDG-PET/CT in early breast cancer upstaging and modification of treatment. Int J Cancer Ther Oncol 2016; 4: 4413
• 2 Groheux D, Cochet A, Humbert O, Alberini J, Hindie E, Mankoff D. 18F-FDG PET/CT for staging and restaging of breast cancer. JNucl Med 2016; 57 Suppl (01) 17S-26S
• 3 Groves A, Shastry M, Ben-Haim S, Kayani I, Malhotra A, Davidson T. et al. Defining the role of PET-CT in staging early breast cancer. Oncologist 2012; 17: 613-9
• 4 Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F. et al. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging 2012; 39: 852-63
• 5 Bernsdorf M, Berthelsen AK, Wielenga VT, Kroman N, Teilum D, Binderup T. et al. Preoperative PET/CT in early stage breast cancer. Ann Oncol 2012; 23: 2277-82
• 6 National Comprehensive Cancer Network. 2016 Breast Cancer (Version 1.2016). Retrieved from: http://www.nccn.org/professionals/physicians_gls/f_guidelines.asp
• 7 Manohar K, Mittal B, Bhoil A, Bhattacharya A, Singh G. Role of 18F-FDG PET/CT in identifying distant metastatic disease missed by conventional imaging in patients with locally advanced breast cancer. Nucl Med Commun 2013; 34: 557-61
• 8 Yang S, Cho N, Moon W. The role of PET/CT for evaluating breast cancer. Korean J Radiol 2007; 8: 429-37
• 9 Heusner T, Kuemmel S, Umutlu L, Koeninger A, Freudenberg L, Hauth E. et al. Breast cancer staging in a single session: Whole-body PET/CT mammography. J Nucl Med 2008; 49: 1215-22
• 10 Groheux D, Giacchetti S, Espie M, Vercellino L, Hamy A, Delord M. et al. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: A prospective study. JNucl Med 2011; 52: 1526-34
• 11 Dubey IP, Jain A, Chauhan MS, Kumar R, Agarwal S, Kishore B. et al. Tumor characteristics and metabolic quantification in carcinoma breast: An institutional experience. Indian J Cancer 2017; 54: 333-9
• 12 Kitajima K, Nakamoto Y, Okizuka H, Onishi Y, Senda M, Suganuma N. et al. Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors. Ann Nucl Med 2008; 22: 595-602
• 13 Koo HR, Park JS, Kang KW, Cho N, Chang JM, Bae MS. et al. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Soc Radiol 2014; 24: 610-8